Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Proline-, glutamic acid- and leucine-rich protein 1
(
PELP1
)/
modulator of nongenomic activity of estrogen receptor
(
MNAR
), a novel coactivator of estrogen receptors (ERs; ERalpha and ERbeta), modulates the genomic and nongenomic functions of the ERs.
PELP1
expression is developmentally regulated in mammary glands and overexpressed in breast tumors. However, little is known about the regulation of
PELP1
. In this study, we examined whether
PELP1
expression is modulated by steroid hormone 17beta-estradiol (E2)-ER pathway. We found that in MCF-7 breast cancer cells, E2 upregulated
PELP1
expression threefold and that this upregulation was reduced by antiestrogen. We also found that E2 modulated
PELP1
levels in an actinomycin-D-sensitive manner, suggesting transcriptional regulation. Cloning and analysis of the 2-kb
PELP1
promoter region revealed two estrogen-responsive element (ERE) half sites in the
PELP1
promoter region. In transient transfection assays, E2 upregulated
PELP1
promoter activity in breast, endometrial and
osteosarcoma
model cancer cell lines in an ICI 182,780-sensitive manner. We demonstrated the recruitment of ER to the
PELP1
promoter in vitro using EMSA assays and in vivo using a chromatin immunoprecipitation assay. The
PELP1
promoter was similarly upregulated by both ERalpha and ERbeta and differentially regulated by selective estrogen receptor modulators in a cell line-dependent manner. Our results suggest that
PELP1
expression is modulated by the E2-ER pathway and that
PELP1
is an ER target gene.
...
PMID:Cloning and functional characterization of PELP1/MNAR promoter. 1508 30